### **Clinical Trials 101**

#### **Peggy Devine**

Founder & President Cancer Information & Support Network,

ACOSOG & ACRIN patient advocate



#### **Bettye Green**

Chair, ACOSOG patient advocate committee

### Overview

What are Clinical Trials?

How to review a Clinical Trial Protocol

How to review a Consent Form

### **What are Clinical Trials**

- Definition
- Why they are Important
- Phases of Clinical Trials
- Barriers
- Benefits
- Risks
- Protections
- Resources

# What are Cancer Clinical Trials?

- Research studies involving people
- They try to answer scientific questions and find better ways to prevent, diagnose, or treat cancer



# Why Are Cancer Clinical Trials Important?

- Cancer affects all of us
- Each year in the U.S.A:
  - > 1,500 people die each day
  - > 1 of 4 deaths is from cancer
  - > The more people that take part, the faster we can:
    - Answer critical research questions
    - Find better treatments and ways to prevent cancer



#### **Clinical Trial Phases**

#### Phase I

- What dose is safe
- A few people in one or two centers

#### Phase II

- safety and effectiveness
- > <100 people in a few centers

#### Phase III

- Compare it against standard of care
- Large numbers of people, around the Country

#### Phase IV

> After drug is approved, further safety and effectiveness

# Barriers to Participation in Clinical Trials

#### Physicians & other providers may:

- Be unwilling to lose control of patient's care
- Believe that standard therapy is best
- Believe that clinical trials are more work
- Worry about the patient's care or how the person will react to suggestion of clinical trial participation

# **Barriers to Participation in Clinical Trials**

#### Patients may:

- > Be unaware of clinical trials
- > Lack access to trials
- > Fear or be suspicious of research
- Have practical or personal obstacles
- Face insurance or cost problems
- Be unwilling to go against their physicians' wishes

## **Benefits of Participation**

#### Possible benefits:

- Subjects may receive, at a minimum, the best standard treatment
- ➤ If the new treatment or intervention is proven to work, subjects may be among the first to benefit
- Subjects have a chance to help others and improve cancer care

## **Risks of Participation**

#### Possible risks:

- New treatments or interventions under study are not always better than, or even as good as, standard care
- Even if a new treatment has benefits, it may not work for every subject
- Health insurance and managed care providers do not always cover clinical trials

## **Protection of Participants**

Nuremberg

 National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research

Belmont Report

National Research Act

# Protecting Participants Before a Trial

- Scientific review by sponsoring organization
- Institutional review board approval
- Informed consent

# Protecting Participants During a Clinical Trial

- Institutional review boards (IRBs)
- Data & safety monitoring boards (DSMBs)
  - Minimize risks
  - > Ensure integrity of data
  - Can stop study if necessary

## **Questions: Ask & Answered**

- What is the study about?
- Who put the study together?
- Where is the trial being conducted?
- What will the I get out of the study?
- What are the risks?
- How long will the study last?
- What tests are involved?

### More Questions: Ask & Answered

- How will I be protected from harm?
- Do I have to pay for any part of the trial?
- Who should be contacted for problems or questions?
- What do I have to do in this study?
- What are my other options?

## **Subject's Decision & Rights**

- The decision to participate is the subject's
- Informed Consent is more than a signature
  - it is a process
    - ➤ All the facts about a study must be given before the patient decides to participate
    - Including details about all treatments and test(s) and the benefits and risks
    - Rights should be fully explained

#### **How to Find Clinical Trials**

#### The Internet

- National Library of Medicine
  - http://www.ClinicalTrials.gov
- Centerwatch Clinical Trials
  - http://www.centerwatch.com
- NCI/CancerNet
  - http://cnetdb.nci.nih.gov/trials.html
  - www.cancer.gov
- Your healthcare provider
- **1-800-4-CANCER (1-800-422-6237)**



# How to Review a Clinical Trial Protocol

- Use ACRIN's project IMPACT template
- Why our review is important
- Basic

## **Project IMPACT**

www.ACRIN.org / project IMPACT

A template designed by advocatesFOR advocates

# Why our Review is Important

- Scientists focus on what they care about
- We provide a reality check: what is do able
- Paper Trail:
  - > Comments on conference calls may not be captured
  - No record of advocate concerns/support
  - No way to track if our concerns where incorporated into protocol
  - No way to capture our accountability to process

#### Structure of all Protocols

- Background / Introduction
- Study Hypothesis
- Study Design
- Rationale / Objective
- Eligibility
- Statistical Design
- Schema / Flowchart
- Informed Consent Process
- Accrual / Communication Plan

## **Background / Introduction**

- What is the question?
- What is the value to patients?
- Will the study help patients live longer?
- How long will it take to complete the trial?
- Will the answer be relevant when the trial is over?

## **Study Hypothesis**

- Define the Hypothesis: so you understand it
- Indicate what kind of study it is
  - Treatment
  - > QOL
  - Surgery
  - Imaging
  - Prevention
  - New dosing
  - New order drugs are given

## **Study Design**

- How does the study design compare to standard of care
- Do you feel that demands on patients are reasonable compared to standard of care? (Yes/No)
- Are correlative studies included? Encourage
- Will this study be conducted in the community? (Yes/No)

## Rationale / Study Objective

- What are the formal trial endpoints?
- Do they compare to the hypothesis goals?
  - For example, if the hypothesis states that the trial will increase survival, but the endpoints don't measure survival, why not?

## **Eligibility**

- Who's included excluded
- Do you think that the trial population is representative of the patient population?
- Will the study be open in sites with diverse populations?

## **Preliminary Statistical Design**

- If the trial examines more than one treatment, are participants randomized to a single treatment
- Is crossover allowed whereby participants may receive some or all of the treatments being studied?
  - Why or why not
  - Do you agree with the trial design?

## **Feasibility**

- Do you think patients will be interested in enrolling? (Yes/No)
- Do you think the numbers expected to enroll are reasonable? (Yes/No)
- Are there aspects of the trial that you think will make accrual more difficult? (Yes/No)
- Diversity:
  - Is there a plan to include a diverse population? (Yes/No)
  - Will the trial be at sites with diverse populations? (Yes/No)

## Schema / Flowchart

- Is the schema designed in a patientfriendly form? (Yes/No)
- Reading left to right, not top to bottom? (Yes/No)
- Other specific comments on how to make it as patient-friendly as possible?

#### **Informed Consent Process**

- Does the protocol describe the informed consent process (Yes/No)
  - Are there Follow-up materials? (Yes/No)
- Is the informed consent based on the new NCI template? (Yes/No)
- What happens in the event of an injury:
- Any correlative studies (i.e. tissue)
  - Use patient's tissue for future studies? (Yes/No)

# How to review a Consent Form

From an Advocate Perspective

#### **The Consent Form**

■ 6-8 Grade Reading Level

Formatting

Study Requirements clear

Other Options Clear

## The Consent Form: Readability

- 6<sup>th</sup>−8<sup>th</sup> Grade level: 14-17 words/sentence; 139-147 syllables/100 words
- Does "readability" = "understanding"
  - Concept words; category words; value judgment word
- Clear Writing Tips <sup>2</sup>
- Word Substitution Lists <sup>3</sup>

<sup>&</sup>lt;sup>1</sup> Hochhauser, M., IRB: Ethics & Human Research 25, no. 5 (2003):7-10

<sup>&</sup>lt;sup>2</sup> Kripalani, S., Texas Medicine, 91(8), 40-45

<sup>&</sup>lt;sup>3</sup> Hilts, L. & Krilyk B. J. (1991). Write readable information to educate.

### The Consent Form: Formatting 1

- Techniques to use:
  - Use font size of 12 or greater
  - Use fonts with "tails", like GRAMMOND, CENTURY or COPPER PLATE LIGHT
  - > Bullet all:
    - study requirements ,headings and risks
  - Use short paragraphs
  - Lots of white space

<sup>&</sup>lt;sup>1</sup> courtesy of Ralph Kennedy

### The Consent Form: What is required

- Techniques to use:
  - List all Treatments
  - List all Tests
  - List extra visits
  - How does that fit into daily life
    - Graphic flowchart <sup>1</sup>

## The Consent Form: Options Are Clear

#### Techniques to use

- List other options
- Not just standard of care
- Compare clinical trial & standard of care 1
- Better distinction between risks and benefits
  - side by side comparison chart <sup>2</sup>

<sup>&</sup>lt;sup>1</sup> **Hochhauser, M.,** "The Informed Consent Form: Document Development", Drug Information Journal, 34 (4) 1309-1317 (2000)

<sup>&</sup>lt;sup>2</sup> CISN

### **Need: Educational Materials**

- Too many elements to process 1
  - > 14 required, 6 optional + 5 HIPPA
    - Decision to participate may be based on what patient is able to process and understand
- Omission neglect: You can't use what you don't see <sup>1</sup>, <sup>2</sup>
  - Compare standard vs. study

<sup>&</sup>lt;sup>1</sup> Hochhauser, M., "Applying Consumer Psychology to Subject Recruitment", actmagazine.com

<sup>&</sup>lt;sup>2</sup> F.R. Kardes and D.M. Sanbonmatsu, "Ommision Neglect, the importance of Missing Information," Skeptical Inquierer, 27(2) 42-46(2003)

### **Need: Educational Materials**

- Learning Styles Matter <sup>1</sup>
- Patients learn best when there is a match between their preferred learning style and the presentation style:
  - Visual Learner
  - Auditory Learner
  - Sensory Learner
  - Kinesthetic Learner

<sup>&</sup>lt;sup>1</sup> Adapted from: Teachers Make The Difference by Susan Kovalik

#### **Need: Educational Materials**


- Study Schema (graphic) <sup>1</sup>, <sup>2</sup>
  - Calendar Format
  - Clear / color coded
- Study Brochure <sup>2</sup>, <sup>3</sup>
  - Address possible hurtles
    - Randomization
    - Placebo

<sup>&</sup>lt;sup>1</sup> CISN


<sup>&</sup>lt;sup>2</sup> Hochhauser, M., "Applying Consumer Psychology to Subject Recruitment", actmagazine.com

<sup>&</sup>lt;sup>3</sup> Doak, L. G., Doak C. C. & Meade, C. D. (1996). Strategies to improve cancer education materials. Onco logy Nursing Forum, 23(8)

## Original Co-operative group Schema



### CISN Version of Study Schema



Study timeline developed for UCSF by Peggy Devine

## **ACRIN Advocate Help**

## MRI of the Contralateral Breast

ACRIN Research Study 6667

An ACRIN Research Study for Women with a Recent Diagnosis of Breast Cancer

> Information for Participants



#### **Breast MRI Study**

Imaging your cancer-free breast



Are you a breast cancer patient with concerns about your healthy breast?



## **Summary**

- Advocates Can Make a Difference
  - When reviewing protocols
  - Helping write the consent form

#### **Thank You**

- Summit Series on Clinic Trials
- Coalition of Cancer Cooperative Groups
- Funders
- ACOSOG and ACRIN
- CISN